Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000
Debt
Debt-to-Equity Ratio0.41
Current Ratio8.95
Quick Ratio8.95
Price-To-Earnings
Trailing P/E Ratio-3.08
Forward P/E Ratio-4.27
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.37 million
Price / Sales35.38
Cash FlowN/A
Price / CashN/A
Book Value$2.04 per share
Price / Book4.25
Profitability
EPS (Most Recent Fiscal Year)($2.59)
Net Income$-127,790,000.00
Net MarginsN/A
Return on Equity-121.07%
Return on Assets-45.51%
Miscellaneous
Employees137
Outstanding Shares54,630,000
Market Cap$538.09 million
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics, Inc. (NASDAQ:CYTK) posted its quarterly earnings data on Thursday, July, 26th. The biopharmaceutical company reported ($0.51) EPS for the quarter, hitting analysts' consensus estimates of ($0.51). The biopharmaceutical company had revenue of $6.22 million for the quarter, compared to analysts' expectations of $5.54 million. View Cytokinetics' Earnings History.
When is Cytokinetics' next earnings date?
What price target have analysts set for CYTK?
7 brokers have issued 1-year price targets for Cytokinetics' stock. Their forecasts range from $10.00 to $21.00. On average, they anticipate Cytokinetics' share price to reach $13.4286 in the next twelve months. This suggests a possible upside of 55.1% from the stock's current price. View Analyst Price Targets for Cytokinetics.
What is the consensus analysts' recommendation for Cytokinetics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.
What are Wall Street analysts saying about Cytokinetics stock?
Here are some recent quotes from research analysts about Cytokinetics stock:
- 1. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (10/3/2018)
- 2. Cantor Fitzgerald analysts commented, "We have an Overweight rating based on expectations for increasingly visible pipeline progress with ome’ in chronic HF and relde’ in SMA, ALS, COPD and frailty. For ome’ development, GALACTIC-HF data are expected in 2021, with interim reads in ’19 (futility) and ’20 (efficacy) that may lead to large milestone payments to CYTK and/or acquisition interest. Recent provocative relde’ P2 data in SMA showed dose/exposure dependent clinical benefit in 6MWD & MEP, which may translate to other indications, as well as enhance PoS in Type III SMA." (10/3/2018)
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include TESARO (TSRO), Pacira Pharmaceuticals (PCRX), Global Blood Therapeutics (GBT), Prestige Consumer Healthcare (PBH), Opko Health (OPK), Allakos (ALLK), Myovant Sciences (MYOV), Theravance Biopharma (TBPH), Nabriva Therapeutics (NBRV), Spectrum Pharmaceuticals (SPPI), Zogenix (ZGNX), Portola Pharmaceuticals (PTLA), G1 Therapeutics (GTHX), Puma Biotechnology (PBYI) and Phibro Animal Health (PAHC).
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
- Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
- Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
- Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
- Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $8.66.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $538.09 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.
What is Cytokinetics' official website?
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
